Olga Chernova
Olga Chernova has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Amy James
Animal research Technical Support, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA
15 shared publications - Baktiar O. Karim
Frederick National Laboratory for Cancer Research
15 shared publications - Brad Gouker
Molecular Histopathology Laboratory, Laboratory Animal Sciences Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA
15 shared publications - Carleen Klumpp-Thomas
National Center for Advancing Translational Sciences
15 shared publications - Catherine Wells
Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland
15 shared publications - Christine M. Heske
Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
15 shared publications
Latest Publications
- Open Access
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
Structural figures of NAMPT inhibitors.
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
Structural figures of NAMPT inhibitors.
- Open Access
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S13 from Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
Time course study design for imaging and OT-82 treatment for hyperpolarized pyruvate 13C-MRSI. Post treatment MRSI was performed 5 hours post OT-82 dose #2.
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S13 from Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
Time course study design for imaging and OT-82 treatment for hyperpolarized pyruvate 13C-MRSI. Post treatment MRSI was performed 5 hours post OT-82 dose #2.
- Open Access
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3. from Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
Cell proliferation rates of HLRCC cell lines treated with low and high concentrations of NAMPT inhibitors. A) Effect of OT-82 at 0.8nM or 100nM (left) and GNE-618 at 8nM or 200nM (right) on cell proliferation of UOK262 after 96 hours. B) Effect of OT-82 at 0.8nM or 100nM (left) and GNE-618 at 8nM or 200nM (right) on cell proliferation of UOK268 after 96 hours. C) Effect of OT-82 at 0.8nM or 100nM (left) and GNE-618 at 8nM or 200nM (right) on cell proliferation of UOK365 after 96 hours.
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3. from Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
Cell proliferation rates of HLRCC cell lines treated with low and high concentrations of NAMPT inhibitors. A) Effect of OT-82 at 0.8nM or 100nM (left) and GNE-618 at 8nM or 200nM (right) on cell proliferation of UOK262 after 96 hours. B) Effect of OT-82 at 0.8nM or 100nM (left) and GNE-618 at 8nM or 200nM (right) on cell proliferation of UOK268 after 96 hours. C) Effect of OT-82 at 0.8nM or 100nM (left) and GNE-618 at 8nM or 200nM (right) on cell proliferation of UOK365 after 96 hours.
- Open Access
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5. from Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
HLRCC spheroid characterization and OT-82 effect on 3D culture. A) UOK262 and (B) UOK365 spheroids plated at different cell densities (8000, 4000, and 2000 cells/well in triplicate) after 24h, showing different degrees of cell aggregation. Cell viability of UOK262 (C) and UOK365 (D) spheroids treated with GNE-618 (1 nM-500 nM) or OT-82 (0.2 nM-100 nM) assessed with Cell-Titer Glo 3D assay decreases in a dose dependent manner.
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5. from Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
HLRCC spheroid characterization and OT-82 effect on 3D culture. A) UOK262 and (B) UOK365 spheroids plated at different cell densities (8000, 4000, and 2000 cells/well in triplicate) after 24h, showing different degrees of cell aggregation. Cell viability of UOK262 (C) and UOK365 (D) spheroids treated with GNE-618 (1 nM-500 nM) or OT-82 (0.2 nM-100 nM) assessed with Cell-Titer Glo 3D assay decreases in a dose dependent manner.
- Open Access
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4. from Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
NAD+ and NADH analysis of UOK365 cells. Analysis of the relative levels of NAD+ and NADH and their ratio after 24 hour treatment of the UOK365 cell line model with a range of concentrations (0.5-100 nM) of either GNE-618 (A-B) or OT-82 (C-D). All levels were compared to cells treated with the amount of DMSO present in the highest concentration of the utilized drugs.
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4. from Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
NAD+ and NADH analysis of UOK365 cells. Analysis of the relative levels of NAD+ and NADH and their ratio after 24 hour treatment of the UOK365 cell line model with a range of concentrations (0.5-100 nM) of either GNE-618 (A-B) or OT-82 (C-D). All levels were compared to cells treated with the amount of DMSO present in the highest concentration of the utilized drugs.
- Open Access
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S12 from Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
In vitro analysis of NAMPT inhibition on glycolysis in FH-deficient tumor cells. (A) Effects of the NAMPT inhibitor OT-82 (100 nM) on the extracellular acidification rate (ECAR) in the UOK262 and UOK365 HLRCC cell lines and the RPTEC normal cell line. (B) Representation of the different effects of OT-82 versus DMSO at time point 5 (designated by a star) after the injection of glucose in UOK262, UOK365, and RPTEC. 2-DG, 2-deoxyglucose.
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S12 from Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
In vitro analysis of NAMPT inhibition on glycolysis in FH-deficient tumor cells. (A) Effects of the NAMPT inhibitor OT-82 (100 nM) on the extracellular acidification rate (ECAR) in the UOK262 and UOK365 HLRCC cell lines and the RPTEC normal cell line. (B) Representation of the different effects of OT-82 versus DMSO at time point 5 (designated by a star) after the injection of glucose in UOK262, UOK365, and RPTEC. 2-DG, 2-deoxyglucose.
- Open Access
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
Validation of MIPE hits in 96-well cytotoxicity screens and comparison of NAMPT inhibitor efficacy across a panel of HLRCC cell lines.
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
Validation of MIPE hits in 96-well cytotoxicity screens and comparison of NAMPT inhibitor efficacy across a panel of HLRCC cell lines.
- Open Access
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
In vivo effects of NAMPT inhibitors in HLRCC xenograft models. Mean body weights are constant throughout the drug study for animals harboring UOK262 xenografts (A) and UOK365 xenografts (B; study shown in Figure 3A-B, n = 10 mice per arm, 95mg/kg OT-82 for 8 week duration). (C-D) H&E stained sections of retinas obtained from NSG mice treated with vehicle or 95mg/kg OT-82 for 5 days. (E-F) Caspase 3 stained sections of retinas obtained from NSG mice treated with vehicle or 95 mg/kg OT-82 for 5 days. Histological sections were evaluated for signs of retinal toxicity by a trained veterinary pathologist. No overt signs of retinal toxicity were observed (n=3 NSG mice).
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
In vivo effects of NAMPT inhibitors in HLRCC xenograft models. Mean body weights are constant throughout the drug study for animals harboring UOK262 xenografts (A) and UOK365 xenografts (B; study shown in Figure 3A-B, n = 10 mice per arm, 95mg/kg OT-82 for 8 week duration). (C-D) H&E stained sections of retinas obtained from NSG mice treated with vehicle or 95mg/kg OT-82 for 5 days. (E-F) Caspase 3 stained sections of retinas obtained from NSG mice treated with vehicle or 95 mg/kg OT-82 for 5 days. Histological sections were evaluated for signs of retinal toxicity by a trained veterinary pathologist. No overt signs of retinal toxicity were observed (n=3 NSG mice).
- Open Access
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
Expression levels of NAD+ biosynthetic and salvage pathway genes in HLRCC tumors, normal kidney samples and pan-kidney data from TCGA. (A) Overview of NAD+ biosynthetic and salvage pathways. (B-E) Box plots for selected NAD+ biosynthetic genes derived from RNA-seq analysis of HLRCC tumors and normal kidney specimens. (F) Box plots for selected NAD+ biosynthetic genes derived from RNA-seq TCGA pan-kidney data. NAMPT (nicotinamide phosphoribosyltransferase), NAPRT (nicotinate phosphoribosyltransferase ), QPRT (quinolinate phosphoribosyltransferase), NMNAT (nicotinamide mononucleotide adenylyl transferase), KIRP (kidney renal papillary cancer), CIMP (CpG island methylator phenotype), PRCC T1/T2 (papillary renal cell carcinoma type 1/type 2), ccRCC (clear cell renal cell carcinoma), ChRCC (chromophobe renal cell carcinoma).
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
Expression levels of NAD+ biosynthetic and salvage pathway genes in HLRCC tumors, normal kidney samples and pan-kidney data from TCGA. (A) Overview of NAD+ biosynthetic and salvage pathways. (B-E) Box plots for selected NAD+ biosynthetic genes derived from RNA-seq analysis of HLRCC tumors and normal kidney specimens. (F) Box plots for selected NAD+ biosynthetic genes derived from RNA-seq TCGA pan-kidney data. NAMPT (nicotinamide phosphoribosyltransferase), NAPRT (nicotinate phosphoribosyltransferase ), QPRT (quinolinate phosphoribosyltransferase), NMNAT (nicotinamide mononucleotide adenylyl transferase), KIRP (kidney renal papillary cancer), CIMP (CpG island methylator phenotype), PRCC T1/T2 (papillary renal cell carcinoma type 1/type 2), ccRCC (clear cell renal cell carcinoma), ChRCC (chromophobe renal cell carcinoma).
- Open Access
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2. from Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
Validation studies to evaluate inhibition of additional HLRCC cell lines by NAMPT inhibitors. A) Effects of the NAMPT inhibitor GNE-618 on cell viability in FH -/- HLRCC cells lines UOK348, UOK271, UOK350, UOK268, UOK365, FH restored UOK268WT and non-transformed kidney epithelial cells RPTEC. Cell viability was assessed by Cell Titer-Glo assay at 96 h. B) Effects of the NAMPT inhibitor OT-82 on cell viability in FH -/- HLRCC cells lines UOK348, UOK271, UOK350, UOK268, UOK365, FH restored UOK268WT and non-transformed kidney epithelial cells RPTEC.
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2. from Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
Validation studies to evaluate inhibition of additional HLRCC cell lines by NAMPT inhibitors. A) Effects of the NAMPT inhibitor GNE-618 on cell viability in FH -/- HLRCC cells lines UOK348, UOK271, UOK350, UOK268, UOK365, FH restored UOK268WT and non-transformed kidney epithelial cells RPTEC. Cell viability was assessed by Cell Titer-Glo assay at 96 h. B) Effects of the NAMPT inhibitor OT-82 on cell viability in FH -/- HLRCC cells lines UOK348, UOK271, UOK350, UOK268, UOK365, FH restored UOK268WT and non-transformed kidney epithelial cells RPTEC.